Finally, it is clear that an understanding of the critical pathways for each KRAS mutant codon [14] and possibly mutational subset (KRAS/STK11 or KRAS/TP53) [17, 18] will be required to target KRAS mutant NSCLC. Here, TP53 is linked to non-small cell lung carcinoma.